SIMPONI indications:
SIMPONI is indicated for the treatment of:1
Psoriatic Arthritis (PsA)
Active and progressive PsA in adult patients when response to disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate, when used alone or in combination with methotrexate (MTX).1
Anklyosing Spondylitis (AS)
Severe, active AS in adults who have responded inadequately to conventional therapy.1
Ulcerative Colitis (UC)
Moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1
Rheumatoid Arthritis (RA)
Moderately to severely active RA in combination with methotrexate, when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.1
SIMPONI is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX.
Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).1